Abstract
Interleukin 10 (IL10) is a pleiotropic cytokine that stimulates various hematopoietic cells. The tumor necrosis factor alpha (TNFα) is a cytokine that may influence the transcriptional activity induced by glucocorticoids. This study examined the impact of TNFα (G308A) and IL10 (G1082A) polymorphisms at promoter regions in relation to the overall survival of 105 children (0 ≤ 18 years) with acute lymphoblastic leukemia (ALL) for a period of 126 months, treated according to the protocol GBTLI99. The G1082A and G308A polymorphisms were identified by allele-specific PCR and PCR-RFLP, respectively. Patients with IL10AA genotype had a higher death ratio (44%, P = 0.0089). Patients with both IL10AA and TNFAA genotypes showed the worst survival when compared with the IL10GG and TNFGA genotypes (P = 0.0043). The results of this study revealed a lower survival among patients with IL10AA genotype and the concomitant occurrence of IL10AA and TNFAA genotypes.
Highlights
Glucocorticoids were among the first drug classes used in the treatment of patients with acute lymphoblastic leukemia (ALL) and are still essential components of treatment [1]
The ratio found in the genotypes for the G308A (TNFα) polymorphism was 1(AA) : 5(AG) : 2.7(GG), and the genotype frequencies were not in Hardy-Weinberg equilibrium (P = 0.0351; A allele proportion = 0.41 and G allele proportion = 0.59)
The ratio of the genotypes for G1082A (IL10) polymorphism was 1(AA) : 1.9(AG) : 1.08(GG), and the genotypic frequencies were in Hardy-Weinberg equilibrium (P = 0.7725; A allele proportion = 0.49 and G allele proportion = 0.51) (Table 1)
Summary
Glucocorticoids were among the first drug classes used in the treatment of patients with ALL and are still essential components of treatment [1]. Prednisone has been the glucocorticoid’s most commonly used drug in the treatment of patients with acute lymphoblastic leukemia (ALL). It is typically given for 4 consecutive weeks in combination with vincristine, anthracycline, asparaginase, and intrathecal chemotherapy. There have been investigations with respect to glucocorticoid receptors [3], distribution of GR isoforms [4], and genetic polymorphisms [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
